A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients
复制标题
DOI：
10.1111/j.1742-1241.2011.02807.x
复制
发表时间：
2011-12-01
影响因子：
2.6
通讯作者：
Storfer, S.
中科院分区：
文献类型：
--
作者：
DeJesus, E.;Mills, A.;Storfer, S.
背景：我们报告了 NEWART 的数据，这是一项随机 4 期临床试验，在 HIV-1 感染的初治患者中以替诺福韦/恩曲他滨 (TDF/FTC) 为背景，比较奈韦拉平 (NVP) 与利托那韦增强阿扎那韦 (ATV/r) 的病毒学疗效和安全性。本研究根据基于 CD4 的 NVP 起始标准招募患者（
Background: We report data from NEWART, a randomised phase 4 clinical trial comparing virologic efficacy and safety of nevirapine (NVP) vs. ritonavir-boosted atazanavir (ATV/r) on a background of tenofovir/emtricitabine (TDF/FTC) in HIV-1-infected treatment-naive patients. This study enrolled patients according to CD4-based initiation criteria for NVP (